Annual Statements Open main menu

NewHydrogen, Inc. - Quarter Report: 2008 June (Form 10-Q)

biosolar_10q-063008.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q
(Mark One)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2008
 
¨ TRANSITION REPORT UNDER SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________ TO __________

COMMISSION FILE NUMBER: 333-138910

 
BIOSOLAR, INC.
(Name of registrant in its charter)

Nevada
 
20-4754291 
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
27936 Lost Canyon Road, Suite 202 , Santa Clarita, CA 91387
(Address of principal executive offices) (Zip Code)

Issuer’s telephone Number: (661) 251-0001

WITH COPIES TO:

Gregory Sichenzia, Esq.
Marcelle S. Balcombe, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32 nd Flr.
New York, New York 10006
(212) 930-9700

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  x No  o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  o No  x
 
The number of shares of registrant’s common stock outstanding, as of July 31, 2008 was 132,666,777.


 
BIOSLAR, INC.INDEX
 

 
   
ITEM 1:
FINANCIAL STATEMENTS (Unaudited)
 
 
Balance Sheets
3
 
Statements of Operations
4
 
Statement of Shareholders' Equity
5
 
Statements of Cash Flows
6
 
Notes to the Financial Statements
7
ITEM 2:
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
9
ITEM 3:
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
12
ITEM 4:
CONTROLS AND PROCEDURES
12
     
PART II: OTHER INFORMATION   
 
     
Item 1:
LEGAL PROCEEDINGS
12
ITEM 1A:
RISK FACTORS
12
ITEM 2:
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
12
ITEM 3:
DEFAULTS UPON SENIOR SECURITIES
13
ITEM 4:
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
13
ITEM 5:
OTHER INFORMATION
13
EXHIBITS
13
 
14


 
PART I –FINANCIAL INFORMATION
 
ITEM 1. FINANCIAL STATEMENTS

BIOSOLAR, INC.
(A Development Stage Company)
FINANCIAL STATEMENTS
JUNE 30, 2008
 


BIOSOLAR, INC.
(A Development Stage Company)
BALANCE SHEETS
JUNE 30, 2008
 
 
   
(Unaudited)
       
   
06/30/08
   
12/31/07
 
             
ASSETS
           
             
CURRENT ASSETS
           
   Cash & cash equivalents
  $
107,480
    $
340,484
 
   Certificates of deposits
   
466,071
     
653,867
 
   Inventory, work in progress
   
60,078
     
-
 
   Other receivable
   
11,207
     
-
 
   Prepaid expenses
   
55,013
     
80,332
 
                 
                        Total Current Assets
   
699,849
     
1,074,683
 
                 
PROPERTY & EQUIPMENT
               
   Machinery and equipment
   
49,130
     
-
 
   Computer
   
1,978
     
1,978
 
   Less: accumulated depreciation
    (2,298 )     (1,029 )
                 
                       Net Property and Equipment
   
48,810
     
949
 
                 
OTHER ASSETS
               
   Patents
   
18,760
     
7,265
 
   Deposit
   
770
     
770
 
                 
                       TOTAL OTHER ASSETS
   
19,530
     
8,035
 
                 
                       TOTAL ASSETS
  $
768,189
    $
1,083,667
 
                 
                 
                 
LIABILITIES AND SHAREHOLDERS' EQUITY
               
                 
CURRENT LIABILITIES
               
   Accounts Payable
  $
19,195
    $
-
 
   Accrued expenses
   
5,807
     
9,611
 
   Credit card payable
   
-
     
995
 
                 
                       TOTAL CURRENT LIABILITIES
   
25,002
     
10,606
 
                 
SHAREHOLDERS' EQUITY
               
   Common stock, $0.0001 par value;
               
   500,000,000 authorized common shares
               
   132,226,777 and 131,706,777 shares issued and outstanding
   
13,222
     
13,170
 
   Additional paid in capital
   
2,311,905
     
2,181,958
 
   Deficit accumulated during the development stage
    (1,581,940 )     (1,122,067 )
                 
                      TOTAL SHAREHOLDERS' EQUITY
   
743,187
     
1,073,061
 
                 
                      TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
  $
768,189
    $
1,083,667
 
 
 
The accompanying notes are an integral part of these financial statements
3

 
BIOSOLAR, INC.
(A Development Stage Company)
STATEMENTS OF OPERATIONS
(Unaudited)
 
 
                           
From Inception
 
                           
April 24, 2006
 
   
Three Months Ended
   
Six Months Ended
   
through
 
   
06/30/08
   
06/30/07
   
06/30/08
   
06/30/07
   
June 30, 2008
 
                               
REVENUE
   
-
     
-
     
-
     
-
     
-
 
                                         
OPERATING EXPENSES
                                       
    Selling and marketing expenses
   
110,333
     
8,660
     
158,511
     
18,944
     
479,133
 
General and administrative expenses
   
125,600
     
76,063
     
250,945
     
160,829
     
902,575
 
Research & Development
   
28,523
     
72,713
     
62,151
     
100,004
     
272,184
 
Depreciation and amortization
   
1,174
     
-
     
1,269
     
633
     
2,339
 
                                         
TOTAL OPERATING EXPENSES
   
265,630
     
157,436
     
472,876
     
280,410
     
1,656,231
 
                                         
LOSS FROM OPERATIONS BEFORE  OTHER INCOME
    (265,630 )     (157,436 )     (472,876 )     (280,410 )     (1,656,231 )
                                         
TOTAL OTHER INCOME
                                       
    Interest income
   
5,411
     
10,062
     
13,803
     
22,957
     
75,891
 
                                         
LOSS BEFORE PROVISION FOR TAXES
    (260,219 )     (147,374 )     (459,073 )     (257,453 )     (1,580,340 )
                                         
    Provision for income taxes
    (800 )    
-
      (800 )     (800 )     (1,600 )
                                         
         NET LOSS
  $ (261,019 )   $ (147,374 )   $ (459,873 )   $ (258,253 )   $ (1,581,940 )
                                         
                                         
BASIC AND DILUTED LOSS PER SHARE
  $ (0.00 )   $ (0.00 )   $ (0.00 )   $ (0.00 )        
                                         
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
                                 
      BASIC AND DILUTED
   
131,750,733
     
128,557,777
     
131,728,755
     
128,557,777
         
                                         
 
 
The accompanying notes are an integral part of these financial statements
4

 
BIOSOLAR, INC.
(A Development Stage Company)
STATEMENT OF SHAREHOLDERS' EQUITY
(Unaudited)
 

                     
Deficit
       
                     
Accumulated
       
               
Additional
   
during the
       
   
Common stock
   
Paid-in
   
Development
       
   
Shares
   
Amount
   
Capital
   
Stage
   
Total
 
                               
Balance at December 31, 2007
   
131,706,777
    $
13,170
    $
2,181,957
    $ (1,122,067 )   $
1,073,060
 
                                         
Issuance of common shares in June 2008 for cash
                                       
(520,000 common shares issued at $0.25 per share ) (unaudited)
   
520,000
     
52
     
129,948
     
-
     
130,000
 
                                         
Net Loss (unaudited)
   
-
     
-
     
-
      (459,873 )     (459,873 )
                                         
Balance at June 30, 2008 (unaudited)
   
132,226,777
    $
13,222
    $
2,311,905
    $ (1,581,940 )   $
743,187
 
 
 
The accompanying notes are an integral part of these financial statements
5

 
BIOSOLAR, INC.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
(Unaudited)
 

   
Six Months
Ended
   
Six Months
Ended
   
From Inception
April 24, 2006
through
 
   
June 30, 2008
   
June 30, 2007
   
June 30, 2008
 
CASH FLOWS FROM OPERATING ACTIVITIES:
                 
Net loss
  $ (459,873 )   $ (258,253 )   $ (1,581,940 )
Adjustment to reconcile net loss to net cash
                       
  used in operating activities
                       
  Depreciation expense
   
1,269
     
633
     
2,298
 
  Issuance of stock for services
   
-
     
-
     
212,260
 
         (Increase) Decrease in:
                       
             Inventory
    (60,078 )    
-
      (60,078 )
             Other receivable
    (11,207 )    
-
      (11,207 )
             Prepaid expenses
   
25,319
      (13,277 )     (55,013 )
 Deposits
   
-
     
-
      (770 )
 Patents
    (11,495 )    
-
      (18,760 )
        Increase (Decrease) in:
                       
             Accounts Payable
   
19,195
      (37,179 )    
19,195
 
             Accrued Expenses
    (3,805 )    
6,904
     
5,807
 
             Credit Card Payable
    (995 )     (2,917 )    
-
 
                         
NET CASH USED IN OPERATING ACTIVITIES
    (501,670 )     (304,089 )     (1,488,208 )
                         
NET CASH FLOWS USED IN INVESTING ACTIVITIES:
                       
    Purchase of Equipment
    (49,130 )    
-
      (51,108 )
    Investment in Certificate of Deposits
   
187,796
     
178,159
      (466,071 )
                         
NET CASH (USED)/PROVIDED BY INVESTING ACTIVITIES
   
138,666
     
178,159
      (517,179 )
                         
NET CASH FLOWS FROM FINANCING ACTIVITIES:
                       
Proceeds from issuance of common stock
   
130,000
     
-
     
2,112,867
 
                         
NET CASH PROVIDED BY FINANCING ACTIVITIES
   
130,000
     
-
     
2,112,867
 
                         
NET INCREASE (DECREASE) IN CASH
    (233,004 )     (125,930 )    
107,480
 
                         
CASH, BEGINNING OF PERIOD
   
340,484
     
200,739
     
-
 
                         
CASH, END OF PERIOD
  $ 
107,480
    $ 
74,809
   
107,480
 
                         
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
                 
   Interest paid
  $
-
    $
-
    $
-
 
   Taxes paid
  $
800
    $
800
    $
1,600
 
 

The accompanying notes are an integral part of these financial statements
6


BIOSOLAR, INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS-UNAUDITED
JUNE 30, 2008
 

1.     Basis of Presentation
The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included.  Operating results for the six month period ended June 30, 2008 are not necessarily indicative of the results that may be expected for the year ending December 31, 2008.  For further information refer to the financial statements and footnotes thereto included in the Company's Form 10-K for the year ended December 31, 2007.
 
Going Concern
The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business.  The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern.  The Company does not generate significant revenue, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern.  The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusion.  As discussed in Note 3, the Company has obtained funds from its shareholders since its’ inception through June 30, 2008. It is Management's plan to generate additional working capital from investors, and then continue to pursue its business plan and purposes.

2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
This summary of significant accounting policies of Carbon Sciences, Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.
 
Development Stage Activities and Operations
The Company is in its initial stages of formation and has insignificant revenues. FASB #7 defines a development stage activity as one in which all efforts are devoted substantially to establishing a new business and even if planned principal operations have commenced, revenues are insignificant.
 
Revenue Recognition
The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, the Company has had no revenues and is in the development stage.
 
Cash and Cash Equivalent
The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
 
Investments
Certificate of Deposits with banking institutions are short-term investments with initial maturities of more than 90 days. The carrying amount of these investments is a reasonable estimate of fair value due to their short-term nature.

7


2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
 
Loss per Share Calculations
The Company adopted Statement of Financial Standards (“SFAS”) No. 128 for the calculation of “Loss per Share”.  SFAS No. 128 dictates the calculation of basic earnings per share and diluted earnings per share. Basic earnings per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the period ended June 30, 2008 as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss.
 
Reclassification
The expenses for the six months ended June 30, 2007 were reclassified to conform with the expenses for the six months ended June 30, 2008.

3.     CAPITAL STOCK
 
During the six months ended June 30, 2008, the Company issued 520,000 shares of common stock at a purchase price of $0.25 per share pursuant to a private placement made pursuant to Rule 506 of Regulation D promulgated under section 4(2) of the Securities Act of 1933, as amended.

4.     INCOME TAXES

The Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2004.
 
The Company adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, on January 1, 2007.  Deferred income taxes have been provided by temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. To the extent allowed by GAAP, we provide valuation allowances against the deferred tax assets for amounts when the realization is uncertain.
 
Included in the balance at June 30, 2008, are no tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.
 
The Company's policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

5.     SUBSEQUENT EVENTS

During July 2008, the Company issued 440,000 shares of common stock for $0.25 per share in the amount of $110,000, pursuant to a private placement made pursuant to Rule 506 of Regulation D promulgated under section 4(2) of the Securities Act of 1933, as amended.

8


ITEM 2:  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
UPDATE

Certain statements contained herein constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. All statements other than statements of historical fact made in this report are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of certain factors, including, but not limited to, risks associated with the integration of businesses following an acquisition, competitors with broader product lines and greater resources, emergence into new markets, the termination of any of our significant contracts, our inability to maintain working capital requirements to fund future operations, or our inability to attract and retain highly qualified management, technical and sales personnel.

Overview
 
We are developing an innovative technology to produce bio-based materials from renewable plant sources that will reduce the cost per watt of Photovoltaic solar cells. Most of the solar industry is focused on photovoltaic efficiency to reduce cost, but we are introducing a new dimension of cost reduction by replacing petroleum-based plastic solar cell components with durable bio-based plastics. The process for producing electricity from sunlight is known as Photovoltaics. Photovoltaic ("PV") is the science of capturing and converting sun light into electricity.

We are focusing our research and product development efforts on producing bio-based components that meet the thermal and durability requirements of current solar cell manufacturing processes for conventional crystalline cell designs as well as thin film PV devices in an effort to capitalize on what we perceive as cost advantages to current petroleum based solar cell components.

We are focusing our research and product development efforts on bio-based backsheets, substrates, superstrates, module, panel components, and the eventual expansion of such products to the building materials.
 
We were incorporated in the State of Nevada on April 24, 2006, as BioSolar Labs, Inc. Our name was changed to BioSolar, Inc. on June 8, 2006. Our principal executive offices are located at 27936 Lost Canyon Road, Suite 202, Santa Clarita, California 91387, and our telephone number is (661) 251-0001. Our fiscal year end is December 31.

Application of Critical Accounting Policies
 
Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using the Black Scholes option pricing model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described items, are reasonable.

9


Use of Estimates

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to recording net revenue, collectibility of accounts receivable, useful lives and impairment of tangible and intangible assets, accruals, income taxes, inventory realization, stock-based compensation expense and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

Fair Value of Financial Instruments

Our cash, cash equivalents, investments, accounts receivable and accounts payable are stated at cost which approximates fair value due to the short-term nature of these instruments.
 
In December 2004, the FASB issued Statement of Financial Accounting Standards No. 123R, Share-based Payment. SFAS 123R revises SFAS 123 and supersedes APB 25. SFAS 123R will be effective for the year ending December 31, 2006, and applies to transactions in which an entity exchanges its equity instruments for goods or services and also applies to liabilities an entity may incur for goods or services that are to follow a fair value of those equity instruments. Under SFAS 123R, we will be required to follow a fair value approach using an option-pricing model, such as the Black Scholes option valuation model, at the date of a stock option grant. The deferred compensation calculated under the fair value method would then be amortized over the respective vesting period of the stock option. The adoption of SFAS 123R will not have a material impact on our results of operations.

Recently Issued Accounting Pronouncements

 
10


RESULTS OF OPERATIONS – THREE AND SIX MONTHS ENDED JUNE 30, 2008 COMPARED TO THE THREE AND SIX MONTHS ENDED JUNE 30, 2007

OPERATING EXPENSES

Selling and Marketing Expenses

Selling and marketing (“S&M”) expenses increased by $101,673 or 1174.05%, to $110,333 for the three months ended June 30, 2008, compared to the prior period. S&M expenses increased by $139,567 or 737%, to $158,511 for the six months ended June 30, 2008, compared to the prior period. S&M expenses increased due to an increase in marketing exposure.

General and Administrative Expenses

General and administrative (“G&A”) expenses increased by $49,537 or 65.13%, to $125,600 for the three months ended June 30, 2008, compared to the prior period. G&A expenses increased by $90,116 or 56.03%, to $250,945 for the six months ended June 30, 2008, compared to the prior period. This increase in G&A expenses was the result of an increase in salaries and professional fees.

Research and Development

Research and Development (“R&D”) expenses decreased by $44,190 or 60.77%, to $28,523 for the three months ended June 30, 2008, compared to the prior period. R&D expenses decreased by $37,853 or 37.85%, to $62,151 for the six months ended June 30, 2008, compared to the prior period. This decrease in R&D expenses was the result of a decrease in fees paid to consultants and testing of products.

Net Loss

Our net loss increased by $113,645 to $261,019 for the three months ended June 30, 2008, compared to the prior period. Net loss increased by $201,620 to $459,873 for the six months ended June 30, 2008, compared to the prior period. Currently the Company is in its development stage and had no revenues.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2008, we had $674,847 of working capital as compared to $1,064,076 as of December 31, 2007. This decrease of $389,229 was due primarily to use of funds for operating activities.

Net cash used in operating activities was $501,670 for the six months ended June 30, 2008, as compared to cash used of $304,089 for the prior period. This increase of $197,581 was primarily attributable to an increase in general and administrative expenses.

Net cash provided by investing activities was $138,666 for the six months ended June 30, 2008, as compared to cash provided of $178,159 for the prior period. The decrease of cash provided in investing activities was primarily due to a decrease in investing in certificate of deposits and the purchase of equipment.

Net cash provided from financing activities during the six months ended June 30, 2008, and 2007 was $130,000 and $0 respectively. The increase in cash provided from financing activities was due to equity financing.

PLAN OF OPERATION AND FINANCING NEEDS
 
We are engaged in the development of new and innovative technology to produce bio-based materials with the intent to reduce the cost per watt of solar cells that convert sun light into electrical energy. We plan to develop bio-based backsheets, substrates, superstrate layer, module, panel components, and thereafter focus our efforts on establishing markets in the building materials.

11

 
Our plan of operation within the next twelve months is to utilize our cash balances to transition from research and development stage to a production stage for the bio-based plastic backsheets and substrates to reduce the cost of solar cells that convert sun light into electrical energy. In addition, during the next twelve months we plan to accelerate the development activity for other solar cell components, commence a test program to determine the physical properties and characteristics that will be most suitable for commercially available solar cell devices, and build prototype solar cells, as we attempt to validate the commercial viability of additional bio-based solar cell components. We believe that our current cash and investment balances will be sufficient to support development activity and general and administrative expenses for the next twelve months. Management estimates that it will require additional cash resources during 2008, based upon its current operating plan and condition. We will be investigating additional financing alternatives, including equity and/or debt financing. There is no assurance that capital in any form would be available to us, and if available, on terms and conditions that are acceptable. If we are unable to obtain sufficient funds during the next twelve months, we may be forced to reduce the size of our organization, which could have a material adverse impact on, or cause us to curtail and/or cease, the development of our products.
 
Off-Balance Sheet Arrangements
 
We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, results of operations, liquidity or capital expenditures.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 
  
n/a
 
ITEM 4T. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (1) accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure; and (2) recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. There was no change to our internal controls or in other factors that could affect these controls during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION
  
ITEM 1. LEGAL PROCEEDINGS

None.
 
ITEM 1A. RISK FACTORS 
 
There are no material changes from the risk factors previously disclosed in the Registrant’s Form 10-K filed on March 31, 2008.
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
None
 
12


ITEM 3. DEFAULTS UPON SENIOR SECURITIES
 
None
 
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
None
 
ITEM 6. EXHIBITS 

 
Description
 
 
 
 
Articles of Incorporation of Biosolar Labs, Inc. filed with the Nevada Secretary of State on April 24, 2006. (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006)
 
 
 
3.2
 
Articles of Amendment of Articles of Incorporation of Biosolar Labs, Inc. filed with the Nevada Secretary of State on May 25, 2006. (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006)
 
 
 
3.3
 
Articles of Amendment of Articles of Incorporation of Biosolar Labs, Inc. filed with the Nevada Secretary of State on June 8, 2006. (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006)
 
 
 
3.4
 
Bylaws of Biosolar, Inc.( Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006)
 
 
 
 
Form of Subscription Agreement dated as of May 26, 2006. (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006)
 
 
 
10.2
 
Form of Subscription Agreement dated as of July 17, 2006. (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006)
 
 
 
10.3
 
Form of Subscription Agreement dated as of October 11, 2006. (Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed with the SEC on November 22, 2006)
 
 
 
14.1
 
Code of Ethics (Incorporated by reference to the Company’s Form 10-K filed with the SEC on March 25, 2008 )
 
 
 
31.1
 
Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Sarbanes-Oxley Section 302 (filed herewith).
 
 
 
32.1
 
Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (filed herewith).

13


SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on August 1, 2008.

 
 
BIOSOLAR
 
 
 
 
By:
/s/ David Lee 
 
 
Chief Executive Officer (Principal Executive Officer ) and
Acting Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
 
 
 
 
14